Home » News » 01/06 » GlaxoSmithKline hopes SDL deal will speed up EMEA approval

GlaxoSmithKline hopes SDL deal will speed up EMEA approval

Date published: 09/01/2006

GlaxoSmithKline (GSK) has signed a deal to speed up translations of its applications to the European Medicines Agency (EMEA). Its contract with British-based SDL International, worth £300,000, will give GSK access to SDL's Global Information Management (GIM) system. GIM is already able to support the EMEA's XML product information standard (PIM), and will help GSK speed up translate submissions into the EU's 20 languages.

The system allows translations to be optimised by utilising techniques such as SDL's centralised translation memory to reuse previous content and SDL Teamworks to assist workforces to collaborate when working on revisions with regulators. "GSK is leading the industry in adoption of the new PIM standard," said GlaxoSmithKline's vice president of operations and systems, Stephen R Hasler.

"SDL has demonstrated thorough understanding of the technical and business issues involved and we anticipate significant time-to-market advantages once this new solution is implemented."

The company provides software or outsourcing services to firms such as Bayer, Siemens, Audi, Deutsche Bank, Microsoft, Morgan Stanley and SAP. Currently SDL has sold over 100,000 licences for its GIM solution.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.